ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...

Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...

CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...

Biliary atresia (BA) is a life-threatening liver disease of infancy in which early surgery can restore bile flow but rarely ...

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cas ...

Cancer cells that have broken away from a primary tumor can lurk in the body for years in a dormant state, evading immune ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Regular exercise supports immune health by improving the circulation of your immune cells and reducing inflammation, but overtraining may weaken defenses.

People often tend to neglect the rule that even with a mild cold, it is important to stay in bed and not go to work, which is ...